A research study of a new combination antibiotic is now underway for people suffering from Crohn’s disease.
Doctors are seeking participants for a clinical study to evaluate Etrolizumab as an induction and maintenance treatment.
Patient with moderately severe Crohn’s disease who have progressed on 1 or more prior treatments can receive study drug or placebo in this double blinded study with the opportunity to get up to 4 years of active medication at the completion of the study
In order to participate, you must have moderate to severe active Crohn’s Disease and be 18 to 80 years old
Other criteria may apply.